Research · Sep 3, 2026
[BVS] Bioventus Thesis 2026: EXOGEN Moat Anchors Deleveraging Bet as OA Pain Decline Decelerates
Bioventus FY2025 showed adj. EBITDA recovering to ~$75M at ~16.5% margins as CEO Tony Bihl's restructuring (non-core divestitures, SG&A reduction, portfolio simplification post-Misonix) improved the cost structure faster than revenue declined (~$455M). EXOGEN bone healing ($112M, 64% gross margin, no approved US LIPUS competitor) provides the earnings quality floor. OA Pain HA injection decline decelerating (-3.6% vs -6.4% prior year) on DUROLANE single-injection adoption and commercial payer shift. FY2026 thesis: leverage declining toward 4x by FY2027 as FCF retires the ~$465M net debt — equity value unlocks from deeply discounted trough multiples if deleveraging math holds.